
To assess the efficacy and safety of zzso zzso in the treatment of de zzso and relapsed zzso involvement in children with primary zzso zzso 

Data from clinical charts were entered into a database for consecutive zzso patients zzso from nine Spanish zzso Diagnosis of zzso involvement was confirmed by zzso zzso and/or CT zzso The dose of zzso zzso used varied from 20 to 50 zzso by zzso 

There were 8 females and 12 zzso mean age zzso years zzso 8 months to 18 zzso The zzso were: 10 zzso 4 zzso 3 primitive zzso zzso and 3 other zzso Fourteen had undergone previous chemotherapy and 12 zzso Nine received concurrent chemotherapy and 2 concurrent zzso Median follow-up was zzso days zzso 12- zzso Patients received a median of 5 doses zzso zzso of zzso zzso A neurological response zzso or zzso was seen in zzso zzso and a zzso response in zzso zzso Median time to neurological progression exceeded 180 days zzso zzso zzso effects were reported in zzso patients, but none was grade zzso 

zzso zzso was well tolerated and zzso in this patient group, but prospective zzso trials are zzso 

